Trials / Active Not Recruiting
Active Not RecruitingNCT04658199
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UCB0107 (bepranemab) | UCB0107 (bepranemab) will be administered in a predefined dosage. Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous |
Timeline
- Start date
- 2020-11-16
- Primary completion
- 2027-12-13
- Completion
- 2027-12-13
- First posted
- 2020-12-08
- Last updated
- 2025-07-29
Locations
11 sites across 4 countries: Belgium, Germany, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT04658199. Inclusion in this directory is not an endorsement.